AXSM
Axsome Therapeutics, Inc.
$235.14
+1.21%
$12.1B
No data for this timeframe.
Vol
Market Cap$12.1B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders9 funds
Inst. Value$1.4B
Inst. Activity5 buys / 0 sells
Insider Activity0B / 10S
Insider Net $-$36.4M
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases3
Recent Activity
Jun 9, 2026
SEC
CEO Herriot Tabuteau files Form 144 to sell 49,670 shares of Axsome Therapeutics (~$12.2M) under a 10b5-1 plan dated 3/1
144 — Impact 4/10
Jun 9, 2026
SEC
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the
8-K — Impact 2/10
Jun 9, 2026
SEC
CEO Herriot and CFO Pizzie exercised stock options and immediately sold the resulting shares in open-market transactions
CLUSTER — Impact 4/10
Jun 9, 2026
Insider
Pizzie Nick sold 33,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Jun 9, 2026
Insider
TABUTEAU HERRIOT sold 49,670 shares
Chief Executive Officer @ $4.95 ($245.9K)
Jun 9, 2026
Insider
Pizzie Nick sold 33,000 shares
Chief Financial Officer @ $3.50 ($115.5K)
Inst.
FMR LLC — ADD
1,181,622 shares ($215.8M)
Inst.
BANK OF AMERICA CORP — ADD
618,033 shares ($112.9M)
Price Targets
$270.28
+10.0% upside
Buy
Current $245.64
Low $200.00
Median $272.00
High $328.81
21 analysts
$200.00
$328.81
Analyst Ratings
10Strong Buy
15Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 5, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| May 5, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.82 ▲ +6.2% | $-1.21 — $-0.05 | 16% YoY | 8 |
| Next Q | $-0.34 ▲ +28.5% | $-0.77 — $0.62 | 64% YoY | 8 |
| Current FY | $-1.71 ▲ +30.2% | $-3.35 — $1.30 | 51% YoY | 8 |
| Next FY | $5.89 ▲ +20.4% | $1.63 — $12.53 | 445% YoY | 9 |
Latest Reports
NEUTRAL
144
4/10
CEO Herriot Tabuteau files Form 144 to sell 49,670 shares of Axsome Therapeutics (~$12.2M) under a 10b5-1 plan dated 3/1
Jun 9, 2026
NEUTRAL
8-K
2/10
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the
Jun 9, 2026
NEUTRAL
Press
3/10
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including p
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $760.7M | — |
| FMR LLC | $215.8M | ADD |
| BANK OF AMERICA CORP | $112.9M | ADD |
| NORGES BANK | $90.5M | NEW |
| MORGAN STANLEY | $89.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Pizzie Nick | M | $0.00 |
| Jun 9, 2026 | TABUTEAU HERRIOT | M | $245.9K |
| Jun 9, 2026 | Pizzie Nick | M | $115.5K |
| Jun 9, 2026 | Pizzie Nick | SELL | $7.9M |
| Jun 9, 2026 | TABUTEAU HERRIOT | SELL | $12.0M |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $1.4B total value (7,759,088 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, BANK. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,164,818 | $760.7M | 53.7% | — |
| 2 | FMR LLC | 1,181,622 | $215.8M | 15.2% | ADD +27.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 618,033 | $112.9M | 8.0% | ADD +71.1% |
| 4 | NORGES BANK | 495,456 | $90.5M | 6.4% | NEW |
| 5 | MORGAN STANLEY | 491,201 | $89.7M | 6.3% | ADD +40.6% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 402,700 | $73.5M | 5.2% | NEW |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 170,000 | $31.0M | 2.2% | NEW |
| 8 | TWO SIGMA INVESTMENTS, LP | 145,597 | $26.6M | 1.9% | DOUBLED +1674.1% |
| 9 | WELLS FARGO & COMPANY/MN | 89,661 | $16.4M | 1.2% | ADD +62.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 927,883 | 1,181,622 | +27.3% | $215.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 361,261 | 618,033 | +71.1% | $112.9M | 2025-Q4 |
| NORGES BANK | NEW | — | 495,456 | — | $90.5M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 8,207 | 145,597 | +1674.1% | $26.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 55,273 | 89,661 | +62.2% | $16.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 753,429 | 361,261 | -52.1% | $43.9M | 2025-Q3 |
| UBS Group AG | TRIM | 595,455 | 212,451 | -64.3% | $25.8M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 8,207 | — | $996.7K | 2025-Q3 |
| NORGES BANK | EXIT | 468,329 | 0 | -100.0% | $0.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 533,902 | 753,429 | +41.1% | $78.7M | 2025-Q2 |
| UBS Group AG | DOUBLED | 288,647 | 595,455 | +106.3% | $62.2M | 2025-Q2 |
| NORGES BANK | NEW | — | 468,329 | — | $48.9M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 41,615 | 55,703 | +33.9% | $5.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 47,005 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | ADD | 147,347 | 288,647 | +95.9% | $33.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 835,089 | 278,786 | -66.6% | $32.5M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 134,400 | — | $15.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 47,005 | — | $5.5M | 2025-Q1 |
| NORGES BANK | EXIT | 403,026 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 524,282 | 835,089 | +59.3% | $70.7M | 2024-Q4 |
| MORGAN STANLEY | ADD | 410,150 | 576,858 | +40.6% | $48.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 47,762 | 147,347 | +208.5% | $12.5M | 2024-Q4 |
| MORGAN STANLEY | ADD | 321,981 | 410,150 | +27.4% | $36.9M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 322,596 | — | $29.0M | 2024-Q3 |
9 unique insiders with 10 transactions. Net insider value: -$36.4M ($0.00 bought, $36.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | M | 33,000 | $0.00 | $0.00 |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | M | 49,670 | $4.95 | $245.9K |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | M | 33,000 | $3.50 | $115.5K |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | SELL | 33,000 | $240.09 | $7.9M |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | SELL | 49,670 | $241.01 | $12.0M |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | M | 49,670 | $0.00 | $0.00 |
| Jun 5, 2026 | Coleman Mark | Director | A | 1,721 | $0.00 | $0.00 |
| Jun 5, 2026 | Mahony Susan | Director | A | 1,721 | $0.00 | $0.00 |
| Jun 5, 2026 | Saad Mark E | Director | A | 1,721 | $0.00 | $0.00 |
| Jun 5, 2026 | JEFFS ROGER | Director | A | 1,721 | $0.00 | $0.00 |
| Jun 2, 2026 | Coleman Mark | Director | SELL | 5,537 | $223.39 | $1.2M |
| Jun 1, 2026 | Coleman Mark | Director | SELL | 6,000 | $230.30 | $1.4M |
| May 29, 2026 | Coleman Mark | Director | SELL | 6,000 | $233.46 | $1.4M |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 233 | $0.00 | $0.00 |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | SELL | 233 | $228.18 | $53.2K |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 233 | $12.95 | $3.0K |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 4,517 | $0.00 | $0.00 |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | SELL | 4,517 | $227.94 | $1.0M |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 4,517 | $12.95 | $58.5K |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | M | 7,500 | $70.73 | $530.5K |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | SELL | 7,500 | $182.42 | $1.4M |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | M | 7,500 | $0.00 | $0.00 |
| Apr 21, 2026 | Murdock Hunter R. | General Counsel | A | 7,224 | $0.00 | $0.00 |
| Apr 21, 2026 | Pizzie Nick | Chief Financial Officer | A | 8,188 | $0.00 | $0.00 |
| Apr 21, 2026 | Maizel Ari | Chief Commercial Officer | A | 7,224 | $0.00 | $0.00 |
| Apr 21, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | A | 24,081 | $0.00 | $0.00 |
| Apr 21, 2026 | Jacobson Mark L. | Chief Operating Officer | A | 8,669 | $0.00 | $0.00 |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | A | 19,663 | $0.00 | $0.00 |
| Feb 26, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | A | 54,623 | $0.00 | $0.00 |
| Feb 26, 2026 | Maizel Ari | Chief Commercial Officer | A | 16,385 | $0.00 | $0.00 |
| Feb 26, 2026 | Murdock Hunter R. | General Counsel | A | 16,385 | $0.00 | $0.00 |
| Feb 26, 2026 | Pizzie Nick | Chief Financial Officer | A | 18,570 | $0.00 | $0.00 |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 35,378 | $2.85 | $100.8K |
| Feb 26, 2026 | Coleman Mark | Director | SELL | 25,000 | $161.11 | $4.0M |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | M | 35,378 | $0.00 | $0.00 |
| Feb 23, 2026 | Coleman Mark | Director | M | 6,250 | $4.95 | $30.9K |
| Feb 23, 2026 | Coleman Mark | Director | M | 6,250 | $0.00 | $0.00 |
| Feb 20, 2026 | Coleman Mark | Director | M | 12,485 | $0.00 | $0.00 |
| Feb 20, 2026 | Coleman Mark | Director | M | 12,485 | $4.95 | $61.8K |
| Feb 10, 2026 | Coleman Mark | Director | M | 5,193 | $0.00 | $0.00 |
| Feb 10, 2026 | Coleman Mark | Director | M | 5,193 | $8.02 | $41.6K |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | M | 32,410 | $8.02 | $259.9K |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | SELL | 32,410 | $185.60 | $6.0M |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | M | 32,410 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 5 neutral. Avg impact: 4.7/10.
NEUTRAL
144
4/10
CEO Herriot Tabuteau files Form 144 to sell 49,670 shares of Axsome Therapeutics (~$12.2M) under a 1
Jun 9, 2026
NEUTRAL
8-K
2/10
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5
Jun 9, 2026
NEUTRAL
CLUSTER
4/10
CEO Herriot and CFO Pizzie exercised stock options and immediately sold the resulting shares in open
Jun 9, 2026
BULLISH
8-K
7/10
Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier
Jun 3, 2026
MIXED
8-K
6/10
Axsome reported Q1 2026 revenue of $191.2M (+57% YoY), slightly above the $190.7M consensus, but net
May 4, 2026
MIXED
PRESS-RELEASE
6/10
Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but G
May 4, 2026
BULLISH
8-K
8/10
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to
Apr 30, 2026
NEUTRAL
DEFA14A
2/10
Axsome Therapeutics is holding its 2026 annual meeting for shareholders to vote on director election
Apr 24, 2026
NEUTRAL
PRESS-RELEASE
3/10
Axsome Therapeutics announced it will report Q1 2026 financial results on May 4, 2026, followed by a
Apr 8, 2026
NEUTRAL
3/10
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific
Jun 4, 2026
BULLISH
8/10
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's dis
May 1, 2026
BULLISH
8/10
Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agit
Apr 30, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 27 analysts: 10 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$270.28 mean target
+10.0% upside
Buy (1.24)
$200.00 Low
$328.81 High
| Metric | Value |
|---|---|
| Current Price | $245.64 |
| Target Low | $200.00 |
| Target Mean | $270.28 |
| Target Median | $272.00 |
| Target High | $328.81 |
| # Analysts | 21 |
| Recommendation | Buy (1.24) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.82 | $-1.21 | $-0.05 | 15.7% | +6.2% | 1↑ 3↓ | $0.2B | 48.2% | 8 |
| Next Q 2026-09-30 |
$-0.34 | $-0.77 | $0.62 | 64.4% | +28.5% | 0↑ 4↓ | $0.3B | 53.8% | 8 |
| Current FY 2026-12-31 |
$-1.71 | $-3.35 | $1.30 | 50.9% | +30.2% | 1↑ 5↓ | $1.0B | 54.4% | 8 |
| Next FY 2027-12-31 |
$5.89 | $1.63 | $12.53 | 445.1% | +20.4% | 3↑ 2↓ | $1.6B | 61.7% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.818 | |
| 7d ago | $-0.818 | |
| 30d ago | $-0.872 | +0.054 |
| 60d ago | $-0.554 | -0.263 |
| 90d ago | $-0.554 | -0.263 |
13 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 5, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 5, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 4, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | UBS | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 24, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 23, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 3, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 15 | 2 | 0 | 0 | 93% | |
| May 1, 2026 | 10 | 15 | 2 | 0 | 0 | 93% | |
| Apr 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Mar 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Jan 1, 2026 | 9 | 16 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 16, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 16, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Why is no one talking about $AXSM?
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
fda
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
<p align="justify">NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new e
Jun 1, 2026
contract
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
<p align="justify">NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new e
Jun 1, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 29, 2026
Clinical Trial
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Phase Phase 3 — COMPLETED
May 27, 2026
other
Axsome Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
May 13, 2026
short_interest
FTD: AXSM — 57,815 shares ($13.0M) failed to deliver
Settlement: 20260513, Price: $224.03, FTD Value: $12,952,294.45, AXSOME THERAPEUTICS INC COM ST
May 12, 2026
short_interest
FTD: AXSM — 39,641 shares ($8.6M) failed to deliver
Settlement: 20260512, Price: $216.47, FTD Value: $8,581,087.27, AXSOME THERAPEUTICS INC COM ST
May 11, 2026
short_interest
FTD: AXSM — 62,981 shares ($13.7M) failed to deliver
Settlement: 20260511, Price: $217.38, FTD Value: $13,690,809.78, AXSOME THERAPEUTICS INC COM ST
May 6, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 6, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 5, 2026
other
Axsome Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
May 4, 2026
earnings
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth</em></p>
May 4, 2026
short_interest
FTD: AXSM — 13,914 shares ($2.9M) failed to deliver
Settlement: 20260504, Price: $206.53, FTD Value: $2,873,658.42, AXSOME THERAPEUTICS INC COM ST
May 4, 2026
earnings_calendar
AXSM Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
fda
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
<p align="justify">NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
Apr 30, 2026
fda
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
<p align="center"><em>AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dem
Apr 30, 2026
fda_pdufa
PDUFA: AXSM — AXS-05 in Alzheimer's disease agitation — 2026-04-30
FDA target action date 2026-04-30 for AXSM (Axsome Therapeutics, Inc.). Drug: AXS-05. Indication: Alzheimer's disease agitation. sNDA for AXS-05 for A
Apr 30, 2026
FDA
AUVELITY
Supplemental Approval — Labeling — DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE — TABLET, EXTENDED RELEASE — ORAL
Apr 8, 2026
earnings
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
<p align="justify">NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new
Mar 11, 2026
short_interest
FTD: AXSM — 15,412 shares ($2.6M) failed to deliver
Settlement: 20260311, Price: $166.34, FTD Value: $2,563,632.08, AXSOME THERAPEUTICS INC COM ST